Oct 2026· Biomaterials· Vol 338 Pt B, pp.
124667
· 0 citations· 38 references
Medicine
TL;DR
Tri@N is established as a dual-functional polymeric nanoplatform that integrates hydrophobic polymer tagging-mediated degradation of a membrane protein with therapeutic payload delivery, providing a versatile strategy for multimodal cancer therapy.
Abstract
Targeted protein degradation (TPD) has emerged as a powerful strategy for eliminating disease-driving proteins, yet its broader application remains constrained by limited target specificity and the lack of integrated therapeutic delivery functions. Here, we report Tri@N, a multimodal polymeric nanoplatform that extends hydrophobic polymer-based TPD to membrane-associated targets while simultaneously enabling immunomodulatory drug delivery. Tri@N is engineered to remain stable during systemic circulation but undergo intracellular disassembly in response to elevated GSH levels. This disassembly exposes hydrophobic polymer segments that function as a hydrophobic polymer tag, promoting EGFR destabilization and degradation through both proteasomal and autophagy-lysosomal pathways. In parallel, Tri@N releases niclosamide (NIC), which suppresses the STAT3/PD-L1 signaling axis. In colorectal cancer models, Tri@N achieved coordinated EGFR degradation and PD-L1 downregulation, resulting in enhanced CD8+ T cell-mediated antitumor immunity and robust tumor suppression in vivo. These findings establish Tri@N as a dual-functional polymeric nanoplatform that integrates hydrophobic polymer tagging-mediated degradation of a membrane protein with therapeutic payload delivery, providing a versatile strategy for multimodal cancer therapy.
Targeted protein degradation (TPD) has fundamentally redefined pharmacological intervention, shifting from classical occupancy-driven inhibition to event-driven elimination of undruggable pathogenic proteins, holding great promise for treating various intractable diseases. Although heterobifunctional degraders and mole...
Le-Yuan Wang, Jian-Hui Yang, Yang Liu et al.· Advanced Healthcare Material...· 0 citations
Delivering therapeutic macromolecules to defined cell populations in vivo remains a central unsolved problem in biomedicine. Proteins, nucleic acids and viral vectors are cleared by phagocytes, degraded by enzymes, blocked by endothelial and interstitial barriers, and trapped in acidifying endolysosomes. Pre-existing i...
Lipid nanoparticles (LNPs) are a leading platform for mRNA delivery, yet improving their performance often requires complex chemical modification or reformulation of core components. Here, we report a modular peptide-coating strategy for post-formulation engineering of LNP interfaces through physical assembly. A modu...
Chuan-Mei Tang, Yu-Zhi Ye, Ji-Wei Min et al.· Biomacromolecules· 0 citations
This work highlights membrane engineering-enabled biological regulation of nanomaterials, offering rational guidelines for the design and scalable fabrication of next-generation biomimetic nanotherapeutics.
Hong-Yu Yang, Xin-Yuan Zhu, You-Fu Wang et al.· ACS Applied Materials and In...· 0 citations
An antitumor peptide-based delivery platform in which both termini of a stapled p53 α-helix are linked via a disulfide bond, thereby repurposing nonpolar residues originally involved in target protein (hDM2) binding as a hydrophobic block that drives co-assembly with doxorubicin.
Jae Yun Lee, M. Park, Sung-Chan Choi et al.· Small· 0 citations
Zein-based gene delivery remains preclinical and requires stronger mechanistic, cargo-specific and route-specific validation, and translational rationale for zein lies not in superior intrinsic transfection efficiency, but in route-specific protection, sustained release, hydrophobic drug co-loading and use as a biodegr...
Dua Alsinglawi, Enass Serry Moursy, Bilgesu Kasurka et al.· International Journal of Bio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.